Research & Development Pipeline
Senexis has built a unique and balanced pipeline of treatments for diseases resulting from the toxicity of amyloid-like proteins.
Click a bar to see more information about that project.
| Hit2Lead | Lead Optimisation | In Vivo Efficacy | Candidate Selection | Pre-Clinical | Phase I | |
|---|---|---|---|---|---|---|
| Alzheimer's Disease |
Series 1 β-Amyloid Aggregation Inhibitor
SEN1500 is the lead compound from a promising series of novel non-peptide small molecules which display robust in vitro and in vivo profiles in protecting against the toxic effect of β-amyloid assemblies. It is being advanced as a potential drug candidate for the treatment of Alzheimer's disease. Series 2 β-Amyloid Aggregation Inhibitor
SEN1576 is the lead compound from a second generation of molecules structurally related to Series 1. Neuroinflammation Inhibitor
SEN1176 is a novel non-peptide small molecule which suppresses β-amyloid1-42-induced macrophage production of nitric oxide, TNF-α, IL-1β and IL-6. It displays good oral bioavailability and in vivo efficacy in a model of learning and memory. SEN1176 has potential for the treatment of chronic neuroinflammatory processes related to brain Aβ deposition in Alzheimer's disease. |
|||||
| Type 2 Diabetes |
Amylin Aggregation Inhibitors
Senexis has discovered a novel series of non-peptide small molecules which protect against the toxic effects of amylin in vitro. These compounds are currently undergoing further characterisation to select candidates for in vivo efficacy studies. |
|||||
The pipeline has been carefully risk adjusted to minimise the impact of early compound attrition and to balance the relative time/cost required to commercialise the different products. We are mainly focused on building a pipeline of potent and selective small molecule, drug-like compounds for the treatment of Alzheimer's disease, which could also have utility in treating Inclusion Body Myositis (IBM).
Our diabetes programmes are at an earlier stage of development and we also have an emerging interest in developing a device to treat Dialysis-Related Amyloidosis (DRA).